SG11201901141WA - Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof - Google Patents

Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof

Info

Publication number: SG11201901141WA
Authority: SG; Singapore
Prior art keywords: international; beijing; science park; pct; crystalline form
Prior art date: 2016-08-16

Application number

SG11201901141WA

Other languages

English (en)

Inventor

Gongyin Shi

Zhiwei Wang

Yunhang Guo

Original Assignee

Beigene Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-08-16

Filing date

2017-08-15

Publication date

2019-03-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61197220&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201901141W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-08-15 Application filed by Beigene Ltd filed Critical Beigene Ltd

2019-03-28 Publication of SG11201901141WA publication Critical patent/SG11201901141WA/en

Links

RNOAOAWBMHREKO-QFIPXVFZSA-N (7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C(C=C)(=O)N1CCC(CC1)[C@@H]1CCNC=2N1N=C(C=2C(=O)N)C1=CC=C(C=C1)OC1=CC=CC=C1 RNOAOAWBMHREKO-QFIPXVFZSA-N 0.000 title 1
102220240796 rs553605556 Human genes 0.000 abstract 3
LPCQBTAOTIZGAE-UHFFFAOYSA-N 2h-pyrimidine-1-carboxamide Chemical compound NC(=O)N1CN=CC=C1 LPCQBTAOTIZGAE-UHFFFAOYSA-N 0.000 abstract 2
239000003795 chemical substances by application Substances 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000008520 organization Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Hematology (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

SG11201901141WA 2016-08-16 2017-08-15 Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof SG11201901141WA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CN2016095510		2016-08-16
PCT/IB2017/054955 WO2018033853A2 (en)	2016-08-16	2017-08-15	Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof

Publications (1)

Publication Number	Publication Date
SG11201901141WA true SG11201901141WA (en)	2019-03-28

Family

ID=61197220

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201901141WA SG11201901141WA (en)	2016-08-16	2017-08-15	Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof

Country Status (16)

Country	Link
US (10)	US10927117B2 (ko)
EP (2)	EP3500575A4 (ko)
JP (3)	JP7402685B2 (ko)
KR (2)	KR20230162137A (ko)
CN (3)	CN116478166A (ko)
AU (3)	AU2017314178B2 (ko)
BR (1)	BR112019003205A8 (ko)
CA (1)	CA3033827A1 (ko)
EA (1)	EA201990519A1 (ko)
IL (2)	IL264784B (ko)
MX (1)	MX2019001900A (ko)
NZ (1)	NZ751418A (ko)
SG (1)	SG11201901141WA (ko)
TW (2)	TWI760356B (ko)
WO (1)	WO2018033853A2 (ko)
ZA (1)	ZA201900919B (ko)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2619125T3 (es)	2013-04-25	2017-06-23	Beigene, Ltd.	Compuestos heterocíclicos fusionados como inhibidores de proteína cinasa
HRP20221262T1 (hr)	2013-09-13	2022-12-09	Beigene Switzerland Gmbh	Protutijela anti-pd1 i njihova uporaba kao terapeutskih i dijagnostičkih sredstava
WO2016000619A1 (en)	2014-07-03	2016-01-07	Beigene, Ltd.	Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
AU2017293423B2 (en)	2016-07-05	2023-05-25	Beigene, Ltd.	Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
CN116478166A (zh)	2016-08-16	2023-07-25	百济神州(苏州)生物科技有限公司	一种化合物的晶型、其制备和用途
EP3500299B1 (en)	2016-08-19	2023-12-13	BeiGene Switzerland GmbH	Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer
US11555038B2 (en)	2017-01-25	2023-01-17	Beigene, Ltd.	Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
CN110799543A (zh)	2017-06-26	2020-02-14	百济神州有限公司	肝细胞癌的免疫治疗
US11377449B2 (en)	2017-08-12	2022-07-05	Beigene, Ltd.	BTK inhibitors with improved dual selectivity
CN111801334B (zh)	2017-11-29	2023-06-09	百济神州瑞士有限责任公司	使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
CN111675711A (zh) *	2019-03-11	2020-09-18	百济神州(苏州)生物科技有限公司	Btk抑制剂化合物的单晶及其制备方法
CN117820311A (zh) *	2019-05-08	2024-04-05	百济神州(苏州)生物科技有限公司	Btk抑制剂及其中间体的制备方法
JP2022534650A (ja)	2019-05-31	2022-08-03	海思科医▲薬▼有限公司	Ｂｔｋ阻害薬環誘導体、その調製方法及びその医薬品適用
EP3981399A4 (en) *	2019-06-10	2023-05-31	BeiGene Switzerland GmbH	ORAL SOLID TABLET WITH A TYROSINE KINAS INHIBITOR AND METHOD OF MANUFACTURE THEREOF
EP3981400A4 (en) *	2019-06-10	2023-07-12	BeiGene Switzerland GmbH	ORAL CAPSULE AND ITS METHOD OF PREPARATION
CN112057432A (zh) *	2019-06-10	2020-12-11	百济神州(苏州)生物科技有限公司	口服胶囊剂及其制备方法
CN112057427A (zh) *	2019-06-10	2020-12-11	百济神州(苏州)生物科技有限公司	一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
CN110563733A (zh) *	2019-09-12	2019-12-13	安帝康（无锡）生物科技有限公司	作为选择性btk抑制剂的咪唑并吡嗪类化合物
KR20220110260A (ko) *	2019-12-04	2022-08-05	허난 즈웨이 바이오메디슨 씨오., 엘티디.	브루톤 티로신 키나제 억제제인 이미다졸 카복사마이드 유도체
CN110922409A (zh) *	2019-12-19	2020-03-27	武汉九州钰民医药科技有限公司	制备btk抑制剂泽布替尼的方法
CN110845504A (zh) *	2019-12-19	2020-02-28	武汉九州钰民医药科技有限公司	合成赞布替尼的新方法
CN110938077B (zh) *	2019-12-25	2021-04-27	武汉九州钰民医药科技有限公司	合成Avapritinib的方法
EP4110331A4 (en) *	2020-02-27	2023-10-04	BeiGene Switzerland GmbH	METHODS OF TREATING DLBCL USING BTK INHIBITORS AND THEIR COMBINATIONS
WO2021259732A1 (en)	2020-06-24	2021-12-30	Sandoz Ag	Multi-component compounds comprising zanubrutinib and a benzoic acid derivative
US20230248833A1 (en)	2020-07-07	2023-08-10	Sichuan Haisco Pharmaceutical Co., Ltd.	Compound having btk kinase degrading activity, and preparation method and pharmaceutical use therefor
WO2022101939A1 (en) *	2020-11-13	2022-05-19	Msn Laboratories Private Limited, R&D Center	Novel process for the preparation of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide or its salts thereof
KR20230107866A (ko) *	2020-11-20	2023-07-18	베이진 스위찰랜드 게엠베하	Btk 억제제를 사용한 전신성 홍반성 루푸스의 치료 방법
EP4259633A1 (en)	2020-12-11	2023-10-18	Teva Pharmaceuticals International GmbH	Processes for the preparation of zanubrutinib and intermediates thereof
WO2022140246A1 (en)	2020-12-21	2022-06-30	Hangzhou Jijing Pharmaceutical Technology Limited	Methods and compounds for targeted autophagy
WO2023014817A1 (en)	2021-08-03	2023-02-09	Syros Pharmaceuticals, Inc.	Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor
IT202100025997A1 (it) *	2021-10-11	2023-04-11	Olon Spa	Processo per la preparazione di zanubrutinib
IT202200009872A1 (it) *	2022-05-12	2023-11-12	Olon Spa	Processo di preparazione di Zanubrutinib in forma amorfa.
CN117430610A (zh) *	2023-10-11	2024-01-23	宁夏医科大学	一种氘代稠合杂环化合物及其制备方法和应用

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE792533A (fr)	1971-12-09	1973-06-08	Int Chem & Nuclear Corp	Nouvelles pyrazolo (1,5a) pyrimidines et leur procede de preparation
JP2778921B2 (ja)	1994-11-18	1998-07-23	三共株式会社	イミダゾピラゾール誘導体
CA2379421A1 (en)	1999-08-27	2001-03-08	Abbott Laboratories	Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors
NZ517758A (en) *	1999-09-17	2004-06-25	Abbott Gmbh & Co	Pyrazolopyrimidines useful as therapeutic agents
AU2001295041A1 (en)	2000-09-08	2002-03-22	California Institute Of Technology	Proteolysis targeting chimeric pharmaceutical
US20020094989A1 (en) *	2000-10-11	2002-07-18	Hale Jeffrey J.	Pyrrolidine modulators of CCR5 chemokine receptor activity
EP1347971B1 (en)	2000-12-21	2006-03-01	Bristol-Myers Squibb Company	Thiazolyl inhibitors of tec family tyrosine kinases
DE60207390T2 (de)	2001-03-09	2006-07-20	Pfizer Products Inc., Groton	Entzündungshemmende benzimidazolverbindungen
JPWO2003004497A1 (ja)	2001-07-05	2004-10-28	住友製薬株式会社	新規複素環化合物
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
ES2635838T3 (es)	2002-08-26	2017-10-05	Takeda Pharmaceutical Company Limited	Compuesto modulador de receptores de calcio y su uso
CN1771231B (zh)	2002-08-26	2011-05-25	武田药品工业株式会社	钙受体调节性化合物及其用途
US20060183746A1 (en)	2003-06-04	2006-08-17	Currie Kevin S	Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7405295B2 (en)	2003-06-04	2008-07-29	Cgi Pharmaceuticals, Inc.	Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7393848B2 (en)	2003-06-30	2008-07-01	Cgi Pharmaceuticals, Inc.	Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
WO2005011597A2 (en)	2003-07-29	2005-02-10	Irm Llc	Compounds and compositions as protein kinase inhibitors
US20050288295A1 (en)	2003-11-11	2005-12-29	Currie Kevin S	Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
US20060178367A1 (en)	2004-11-10	2006-08-10	Currie Kevin S	Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
US8101770B2 (en)	2004-12-16	2012-01-24	Vertex Pharmaceuticals Incorporated	Pyridones useful as inhibitors of kinases
CA2601628C (en)	2005-03-10	2014-05-13	Cgi Pharmaceuticals, Inc.	Certain substituted amides, method of making, and method of use thereof
CA2620352A1 (en)	2005-08-29	2007-03-08	Vertex Pharmaceuticals Incorporated	3, 5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
CA2620269A1 (en)	2005-08-29	2007-03-08	Vertex Pharmaceuticals Incorporated	3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
WO2007026720A1 (ja) *	2005-08-31	2007-03-08	Taisho Pharmaceutical Co., Ltd.	縮環ピラゾール誘導体
BRPI0617100A2 (pt)	2005-09-01	2011-07-12	Astellas Pharma Inc	composto derivado de piridazinona, composição farmacêutica, método para previnir ou tratar uma doença e uso de um composto derivado de piridazinona
US7625880B2 (en)	2006-01-13	2009-12-01	Pharmacyclics, Inc.	Inhibitors of tyrosine kinases and uses thereof
JP5682051B2 (ja)	2006-05-18	2015-03-11	ファーマサイクリックス，インク．	細胞内キナーゼ阻害剤
TWI398252B (zh)	2006-05-26	2013-06-11	Novartis Ag	吡咯并嘧啶化合物及其用途
AR063706A1 (es)	2006-09-11	2009-02-11	Cgi Pharmaceuticals Inc	Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
AR063946A1 (es)	2006-09-11	2009-03-04	Cgi Pharmaceuticals Inc	Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
JP2010502751A (ja)	2006-09-11	2010-01-28	シージーアイファーマシューティカルズ，インコーポレイティド	キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
PE20081370A1 (es)	2006-09-11	2008-11-28	Cgi Pharmaceuticals Inc	Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
EP2081435B1 (en)	2006-09-22	2016-05-04	Pharmacyclics LLC	Inhibitors of bruton's tyrosine kinase
KR20090063240A (ko)	2006-10-06	2009-06-17	아이알엠 엘엘씨	단백질 키나제 억제제 및 그의 사용 방법
US8987233B2 (en)	2006-11-03	2015-03-24	Pharmacyclics, Inc.	Bruton's tyrosine kinase activity probe and method of using
EP2125819B1 (en)	2007-03-21	2014-10-22	Bristol-Myers Squibb Company	Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
WO2008144253A1 (en)	2007-05-14	2008-11-27	Irm Llc	Protein kinase inhibitors and methods for using thereof
CL2008002793A1 (es)	2007-09-20	2009-09-04	Cgi Pharmaceuticals Inc	Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
US7989465B2 (en)	2007-10-19	2011-08-02	Avila Therapeutics, Inc.	4,6-disubstituted pyrimidines useful as kinase inhibitors
US7982036B2 (en)	2007-10-19	2011-07-19	Avila Therapeutics, Inc.	4,6-disubstitued pyrimidines useful as kinase inhibitors
CA2701275C (en)	2007-10-23	2016-06-21	F. Hoffmann-La Roche Ag	Kinase inhibitors
CN101952283B (zh)	2007-12-14	2013-04-17	霍夫曼-拉罗奇有限公司	咪唑并[1，2-a]吡啶和咪唑并[1，2-b]哒嗪衍生物
RU2505538C2 (ru)	2008-02-05	2014-01-27	Ф.Хоффманн-Ля Рош Аг	Новые пиридиноны и пиридазиноны
US8426424B2 (en)	2008-05-06	2013-04-23	Cgi Pharmaceuticals, Inc.	Certain substituted amides, method of making, and method of use thereof
US8338439B2 (en)	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
MX360970B (es)	2008-06-27	2018-11-23	Avila Therapeutics Inc	Compuestos de heteroarilo y usos de los mismos.
PT2300459E (pt)	2008-07-02	2013-07-04	Hoffmann La Roche	Novas fenilpirazinonas utilizadas como inibidores de cinase
CN102066370B (zh)	2008-07-15	2014-05-14	霍夫曼-拉罗奇有限公司	苯基-咪唑并吡啶类和哒嗪类
CN102159214A (zh)	2008-07-16	2011-08-17	药品循环公司	用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
CA2725512C (en)	2008-07-18	2016-06-28	F. Hoffmann-La Roche Ag	Novel phenylimidazopyrazines
US8476430B2 (en)	2008-07-24	2013-07-02	Bristol-Myers Squibb Company	Fused heterocyclic compounds useful as kinase modulators
MY156789A (en)	2008-09-05	2016-03-31	Celgene Avilomics Res Inc	Algorithm for designing irreversible inhibitors
CN102271515B (zh)	2008-10-31	2014-07-02	健泰科生物技术公司	吡唑并嘧啶jak抑制剂化合物和方法
US20120028981A1 (en)	2008-11-05	2012-02-02	Principia Biopharma Inc.	Kinase Knockdown Via Electrophilically Enhanced Inhibitors
WO2010056875A1 (en)	2008-11-12	2010-05-20	Cgi Pharmaceuticals, Inc.	Pyridazinones and their use as btk inhibitors
US8426428B2 (en)	2008-12-05	2013-04-23	Principia Biopharma, Inc.	EGFR kinase knockdown via electrophilically enhanced inhibitors
WO2010068806A1 (en)	2008-12-10	2010-06-17	Cgi Pharmaceuticals, Inc.	Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
WO2010068788A1 (en)	2008-12-10	2010-06-17	Cgi Pharmaceuticals, Inc.	Heterocyclic amides as btk inhibitors
WO2010068810A2 (en)	2008-12-10	2010-06-17	Cgi Pharmaceuticals, Inc.	Certain substituted amides, method of making, and method of use thereof
WO2010080481A1 (en)	2008-12-19	2010-07-15	Bristol-Myers Squibb Company	Carbazole carboxamide compounds useful as kinase inhibitors
US9266890B2 (en)	2009-01-06	2016-02-23	Dana-Farber Cancer Institute, Inc.	Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
US8299077B2 (en)	2009-03-02	2012-10-30	Roche Palo Alto Llc	Inhibitors of Bruton's tyrosine kinase
CA2748414A1 (en)	2009-04-24	2010-10-28	F. Hoffmann-La Roche Ag	Inhibitors of bruton's tyrosine kinase
EP2424368B1 (en)	2009-04-29	2014-12-31	Locus Pharmaceuticals, Inc.	Pyrrolotriazine compounds
US8586751B2 (en)	2009-06-12	2013-11-19	Bristol-Myers Squibb Company	Nicotinamide compounds useful as kinase modulators
AR077468A1 (es)	2009-07-09	2011-08-31	Array Biopharma Inc	Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP2464647B1 (en)	2009-08-11	2016-09-21	Bristol-Myers Squibb Company	Azaindazoles as btk kinase modulators and use thereof
WO2011029043A1 (en)	2009-09-04	2011-03-10	Biogen Idec Ma Inc.	Heteroaryl btk inhibitors
AR078320A1 (es)	2009-09-04	2011-11-02	Biogen Idec Inc	Derivados nitrogenados heterociclicos inhibidores de tirosinquinasas de bruton(btk), formulaciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades autoinmunes, inflamatorias y canceres.
US7741330B1 (en) *	2009-10-12	2010-06-22	Pharmacyclics, Inc.	Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
CA2798634C (en)	2010-05-07	2019-04-16	Gilead Connecticut, Inc.	Pyridone and aza-pyridone compounds and methods of use
PL2578585T3 (pl)	2010-05-31	2017-01-31	Ono Pharmaceutical Co., Ltd.	Pochodna purynonu jako inhibitor kinazy btk
NZ717373A (en)	2010-06-03	2017-11-24	Pharmacyclics Llc	The use of inhibitors of bruton’s tyrosine kinase (btk)
US8685969B2 (en)	2010-06-16	2014-04-01	Bristol-Myers Squibb Company	Carboline carboxamide compounds useful as kinase inhibitors
CA2803056C (en)	2010-06-23	2017-05-16	Hanmi Science Co., Ltd.	Fused pyrimidine derivatives for inhibition of tyrosine kinase activity
US20120053189A1 (en)	2010-06-28	2012-03-01	Pharmacyclics, Inc.	Btk inhibitors for the treatment of immune mediated conditions
CN103096716B (zh)	2010-08-10	2016-03-02	西建阿维拉米斯研究公司	Btk抑制剂的苯磺酸盐
AR082590A1 (es)	2010-08-12	2012-12-19	Hoffmann La Roche	Inhibidores de la tirosina-quinasa de bruton
CN103201277B (zh)	2010-09-01	2015-11-25	吉利德康涅狄格有限公司	哒嗪酮、其制备方法及使用方法
BR112013007506A2 (pt)	2010-09-01	2016-07-12	Genentech Inc	piridinonas/pirazinonas - métodos de criação e de uso
US8703767B2 (en)	2011-04-01	2014-04-22	University Of Utah Research Foundation	Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors
CA2760174A1 (en)	2011-12-01	2013-06-01	Pharmascience Inc.	Protein kinase inhibitors and uses thereof
CN103596958A (zh)	2011-04-20	2014-02-19	葛兰素集团有限公司	用作抗结核病化合物的四氢吡唑并[1,5-a]嘧啶
US9376438B2 (en)	2011-05-17	2016-06-28	Principia Biopharma, Inc.	Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
WO2012158810A1 (en)	2011-05-17	2012-11-22	Principia Biopharma Inc.	Tyrosine kinase inhibitors
JP5974084B2 (ja)	2011-05-17	2016-08-23	プリンシピアバイオファーマインコーポレイテッド	チロシンキナーゼ阻害剤
MX345170B (es)	2011-05-17	2017-01-19	Hoffmann La Roche	Inhibidores de la tirosina-cinasa de bruton.
CN106831732B (zh)	2011-06-10	2019-12-24	默克专利有限公司	生产具有btk抑制活性的嘧啶和吡啶化合物的组合物和方法
MX2014000338A (es)	2011-07-08	2014-05-01	Novartis Ag	Derivados de pirrolo-pirimidina novedoso.
ES2619125T3 (es) *	2013-04-25	2017-06-23	Beigene, Ltd.	Compuestos heterocíclicos fusionados como inhibidores de proteína cinasa
HRP20221262T1 (hr)	2013-09-13	2022-12-09	Beigene Switzerland Gmbh	Protutijela anti-pd1 i njihova uporaba kao terapeutskih i dijagnostičkih sredstava
AU2014339816B2 (en)	2013-10-25	2020-05-28	Pharmacyclics Llc	Treatment using Bruton's tyrosine kinase inhibitors and immunotherapy
WO2016000619A1 (en)	2014-07-03	2016-01-07	Beigene, Ltd.	Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
WO2016008411A1 (en) *	2014-07-18	2016-01-21	Beigene, Ltd.	5-amino-4-carbamoyl-pyrazole compounds as selective and irreversible t790m over wt-egfr kinase inhibitors and use thereof
SI3179992T1 (sl)	2014-08-11	2022-09-30	Acerta Pharma B.V.	Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1
CA2958139A1 (en)	2014-08-14	2016-02-18	Assia Chemical Industries Ltd.	Solid state forms of ibrutinib
WO2016087994A1 (en)	2014-12-05	2016-06-09	Acerta Pharma B.V.	Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
ES2843323T3 (es) *	2014-12-18	2021-07-16	Principia Biopharma Inc	Tratamiento de pénfigo
DK3236943T3 (da) *	2014-12-24	2023-04-11	Principia Biopharma Inc	Sammensætninger til ileo-jejunal lægemiddeladministration
US9717745B2 (en)	2015-03-19	2017-08-01	Zhejiang DTRM Biopharma Co. Ltd.	Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
WO2017046746A1 (en)	2015-09-15	2017-03-23	Acerta Pharma B.V.	Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
WO2017059224A2 (en)	2015-10-01	2017-04-06	Gilead Sciences, Inc.	Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
JP6875407B2 (ja)	2016-02-19	2021-05-26	ジエンスヘンルイメデイシンカンパニーリミテッドＪｉａｎｇｓｕＨｅｎｇｒｕｉＭｅｄｉｃｉｎｅＣｏ．，Ｌｔｄ．	Ｊａｋキナーゼ阻害剤またはその薬剤的に許容される塩を含有する医薬組成物
CN116478166A (zh)	2016-08-16	2023-07-25	百济神州(苏州)生物科技有限公司	一种化合物的晶型、其制备和用途
EP3500299B1 (en)	2016-08-19	2023-12-13	BeiGene Switzerland GmbH	Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer
CN108778281B (zh)	2016-11-25	2021-09-03	江苏恒瑞医药股份有限公司	一种吡啶酮类衍生物药物组合物及其制备方法
US11555038B2 (en)	2017-01-25	2023-01-17	Beigene, Ltd.	Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
WO2018193105A1 (en)	2017-04-20	2018-10-25	Adc Therapeutics Sa	Combination therapy
CN110799543A (zh)	2017-06-26	2020-02-14	百济神州有限公司	肝细胞癌的免疫治疗
US11377449B2 (en)	2017-08-12	2022-07-05	Beigene, Ltd.	BTK inhibitors with improved dual selectivity
CN111801334B (zh)	2017-11-29	2023-06-09	百济神州瑞士有限责任公司	使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
BR112020019082A2 (pt)	2018-03-21	2020-12-29	Mei Pharma, Inc.	Terapia combinada
EP3981400A4 (en)	2019-06-10	2023-07-12	BeiGene Switzerland GmbH	ORAL CAPSULE AND ITS METHOD OF PREPARATION
EP3981399A4 (en)	2019-06-10	2023-05-31	BeiGene Switzerland GmbH	ORAL SOLID TABLET WITH A TYROSINE KINAS INHIBITOR AND METHOD OF MANUFACTURE THEREOF
US20220281876A1 (en)	2019-07-26	2022-09-08	Beigene, Ltd.	Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
JP2022548212A (ja)	2019-09-11	2022-11-17	ベイジーンリミテッド	マルチチロシンキナーゼ阻害剤及び免疫チェックポイント阻害剤を含む組合せを用いた癌の治療
JP2023503230A (ja)	2019-11-21	2023-01-27	ベイジーンリミテッド	Ｐｉ３キナーゼデルタ阻害剤との組合せで抗ｏｘ４０抗体を用いる癌治療の方法
EP4110331A4 (en)	2020-02-27	2023-10-04	BeiGene Switzerland GmbH	METHODS OF TREATING DLBCL USING BTK INHIBITORS AND THEIR COMBINATIONS

2017
- 2017-08-15 CN CN202310119012.5A patent/CN116478166A/zh active Pending
- 2017-08-15 WO PCT/IB2017/054955 patent/WO2018033853A2/en unknown
- 2017-08-15 CN CN201780049930.8A patent/CN109563099B/zh active Active
- 2017-08-15 CN CN202310094009.2A patent/CN116478165A/zh active Pending
- 2017-08-15 EP EP17841172.4A patent/EP3500575A4/en active Pending
- 2017-08-15 MX MX2019001900A patent/MX2019001900A/es unknown
- 2017-08-15 US US16/325,447 patent/US10927117B2/en active Active
- 2017-08-15 BR BR112019003205A patent/BR112019003205A8/pt active Search and Examination
- 2017-08-15 EP EP24160079.0A patent/EP4353322A2/en active Pending
- 2017-08-15 EA EA201990519A patent/EA201990519A1/ru unknown
- 2017-08-15 TW TW106127682A patent/TWI760356B/zh active
- 2017-08-15 IL IL264784A patent/IL264784B/en unknown
- 2017-08-15 TW TW111117667A patent/TW202233628A/zh unknown
- 2017-08-15 SG SG11201901141WA patent/SG11201901141WA/en unknown
- 2017-08-15 NZ NZ751418A patent/NZ751418A/en unknown
- 2017-08-15 IL IL293319A patent/IL293319A/en unknown
- 2017-08-15 CA CA3033827A patent/CA3033827A1/en active Pending
- 2017-08-15 KR KR1020237039678A patent/KR20230162137A/ko not_active Application Discontinuation
- 2017-08-15 JP JP2019508889A patent/JP7402685B2/ja active Active
- 2017-08-15 KR KR1020197007529A patent/KR102604975B1/ko active IP Right Grant
- 2017-08-15 AU AU2017314178A patent/AU2017314178B2/en active Active
2019
- 2019-02-13 ZA ZA2019/00919A patent/ZA201900919B/en unknown
2021
- 2021-01-12 US US17/146,855 patent/US20210130363A1/en not_active Abandoned
2022
- 2022-01-17 AU AU2022200278A patent/AU2022200278B2/en active Active
- 2022-03-01 JP JP2022030942A patent/JP7413419B2/ja active Active
- 2022-05-10 US US17/740,877 patent/US20220274994A1/en not_active Abandoned
- 2022-05-10 US US17/740,882 patent/US11591340B2/en active Active
- 2022-07-06 US US17/858,826 patent/US11884674B2/en active Active
- 2022-07-06 US US17/858,827 patent/US11814389B2/en active Active
- 2022-09-02 US US17/901,951 patent/US11851437B2/en active Active
2023
- 2023-03-07 US US18/118,555 patent/US20230242542A1/en active Pending
- 2023-11-03 US US18/386,777 patent/US20240092786A1/en active Pending
- 2023-12-01 US US18/526,535 patent/US11970500B1/en active Active
- 2023-12-27 JP JP2023220256A patent/JP2024026550A/ja active Pending
2024
- 2024-01-03 AU AU2024200030A patent/AU2024200030A1/en active Pending

Also Published As

Publication number	Publication date
WO2018033853A2 (en)	2018-02-22
BR112019003205A8 (pt)	2023-01-17
EA201990519A1 (ru)	2019-08-30
CN116478166A (zh)	2023-07-25
IL264784B (en)	2022-07-01
US20220274994A1 (en)	2022-09-01
US20220281881A1 (en)	2022-09-08
AU2017314178B2 (en)	2021-11-18
US20230057716A1 (en)	2023-02-23
AU2017314178A1 (en)	2019-04-04
CA3033827A1 (en)	2018-02-22
US11814389B2 (en)	2023-11-14
US20230242542A1 (en)	2023-08-03
KR102604975B1 (ko)	2023-11-24
CN109563099B (zh)	2023-02-03
CN109563099A (zh)	2019-04-02
US11884674B2 (en)	2024-01-30
MX2019001900A (es)	2019-07-01
US10927117B2 (en)	2021-02-23
JP2024026550A (ja)	2024-02-28
US20240116940A1 (en)	2024-04-11
ZA201900919B (en)	2020-10-28
IL264784A (ko)	2019-03-31
TW202233628A (zh)	2022-09-01
KR20230162137A (ko)	2023-11-28
JP7402685B2 (ja)	2023-12-21
CN116478165A (zh)	2023-07-25
TW201811794A (zh)	2018-04-01
US20220340583A1 (en)	2022-10-27
US20240059699A1 (en)	2024-02-22
KR20190032613A (ko)	2019-03-27
WO2018033853A3 (en)	2018-11-01
EP3500575A2 (en)	2019-06-26
IL293319A (en)	2022-07-01
JP7413419B2 (ja)	2024-01-15
US20240092786A1 (en)	2024-03-21
JP2019528276A (ja)	2019-10-10
NZ751418A (en)	2023-04-28
US11970500B1 (en)	2024-04-30
AU2022200278B2 (en)	2023-10-12
US11851437B2 (en)	2023-12-26
US20220340584A1 (en)	2022-10-27
EP4353322A2 (en)	2024-04-17
US11591340B2 (en)	2023-02-28
EP3500575A4 (en)	2020-04-08
BR112019003205A2 (pt)	2019-06-18
TWI760356B (zh)	2022-04-11
AU2024200030A1 (en)	2024-01-25
US20190169201A1 (en)	2019-06-06
JP2022071072A (ja)	2022-05-13
US20210130363A1 (en)	2021-05-06
AU2022200278A1 (en)	2022-02-10

Publication	Publication Date	Title
SG11201901141WA (en)	2019-03-28	Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
SG11201906209SA (en)	2019-08-27	Bicyclic compounds as allosteric shp2 inhibitors
SG11201811470PA (en)	2019-01-30	Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201810116VA (en)	2018-12-28	Exosomes comprising therapeutic polypeptides
SG11201803920TA (en)	2018-06-28	Compounds and compositions useful for treating disorders related to ntrk
SG11201811225RA (en)	2019-01-30	Ar+ breast cancer treatment methods
SG11201810965YA (en)	2019-01-30	1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201809470RA (en)	2018-11-29	Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals
SG11201808222RA (en)	2018-10-30	Methods of treatment of cholestatic diseases
SG11201906436VA (en)	2019-08-27	Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201808221QA (en)	2018-10-30	1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors
SG11201903061YA (en)	2019-05-30	Combination treatments comprising administration of imidazopyrazinones
SG11201806868TA (en)	2018-09-27	Compositions and methods for protecting against airborne pathogens and irritants
SG11201901063SA (en)	2019-03-28	Therapeutic agents for neurodegenerative diseases
SG11201809534UA (en)	2018-12-28	Methods of treating autoimmune disease using allogeneic t cells
SG11201811209QA (en)	2019-01-30	Oral gastroretentive formulations and uses thereof
SG11201805755SA (en)	2018-08-30	Methods of administering hepcidin
SG11201811580SA (en)	2019-01-30	Compositions, devices, and methods for the treatment of alcohol use disorder
SG11201809882XA (en)	2018-12-28	Pharmaceutical combinations for treating cancer
SG11201901048VA (en)	2019-03-28	Pharmaceutical compositions and uses directed to lysosomal storage disorders
SG11201908691PA (en)	2019-10-30	Compounds and methods for the treatment of parasitic diseases
SG11201810940XA (en)	2019-01-30	Methods of treating pancreatic cancer
SG11201807404XA (en)	2018-09-27	Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
SG11201806424TA (en)	2018-08-30	Therapeutic compounds
SG11201901689YA (en)	2019-03-28	Compounds for treating diseases associated with a mitochondrial dysfonction